Aoki Diabetes Research Institute Inc

The Aoki Diabetes Research Institute (ADRI), located in Sacramento, California, is a non-profit organization founded in 1986 by Thomas T. Aoki, M.D. to further research efforts in diabetes and metabolio.  ADRI is supported by generous supporters and friends.  

In 2021 the CDC stated that diabetes was the 8th leading cause of death in the United States, with an estimated cost of $412.9 billion which includes: $306.6 billion in direct medical costs and $106.3 billion in indirect cost attributable to diabetes.  

Major complications include loss of eyesight, lower limb amputations, kidney failure, retinopathy,  coma, low or high blood pressure, and debilitating nerve diseases.  These nerve diseases are commonly referred to as neuropathy and disrupt normal body functions such as digestion and the ability to sense injuries to the feet that can lead to further complications.

DR. Thomas T. Aoki developed a revolutionary breakthrough in the treatment of diabetes known as Metabolic Activation Therapy (MAT® treatment) while he was a researcher and physician at Harvard Medical School (Joslin Diabetes Center and Brigham and Women's Hospital). 

The patented MAT®procedure slows the progression of or improves diabetic complications.  The treatment consists of precisely calculated doses of intravenous insulin given very rapidly together with the ingestion of glucose. Patients who receive this treatment can lead a more productive aquality of life.  Patients see MAT®treatment as the difference between active, productive lives and lives of disability, deterioration, and probable death from diabetic complications.  Employers realize an increase in productivity and a decrease absences of valued employees.   

The addition of MAT®treatment to currently recommended therapy can reduce hypoglycemia (dangerously low blood sugar) unawareness and resolve, stabilize or delay many complications of diabetes.                                                                       Complications include nephropathy (kidney damage); retinopathy (damage to the retina of the eye); orthostatic hypotension (low blood pressure); gastroparesis (slow emptying of the stomach); foot & venous (stasis) ulcers that are difficult to heal; and painful neuropathy of the feet and legs.  In addition to improving or stabilizing diabetic complications, this treatment given regularly prevents further complications from appearing.  

At this time, MAT®treatments are indicated for patients with diabetes who have progressive diabetic complications despite following the recommended treatment guidelines of the American Diabetes Association and American Association of Clinical Endocrinologists.  For over 38 years, The Aoki Diabetes Research Institute has provided MAT®treatments for both clinical and research patients.

With further research, Dr. Thomas Aoki is discovering that non-diabetics in poor health are seeing huge benefits as well in regards to hospital stays lessened after surgeries and healing accelerated.  Heart patients are seeing improvements in different aspects of their health and lives.

Currently, few can receive this amazing treatment but Dr. Aoki's determination on helping to get this treatment to all who need it and with your generous one-time or ongoing support through this platform will make a big difference in so many lives.